Regeneron to Announce 2024 Financial Results and Host Conference Call

TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that it will release its financial reports for the fourth quarter and full year 2024 on Tuesday, February 4, 2025. This announcement will occur prior to the opening of U.S. financial markets.

The company will also hold a conference call and webcast to discuss these results at 8:30 AM Eastern Time on the same day.

How to Join the Conference Call

Participants interested in listening to the conference call live can do so via a webcast available on Regeneron's 'Investors and Media' section of their website at Regeneron Investors. For those who wish to join by phone, it is necessary to register in advance using a provided link. After registering, telephone participants will receive a confirmation email with details for joining the call, including a unique passcode and registrant ID.

A replay and transcript of both the conference call and the webcast will be accessible on the company's website for at least 30 days following the event.

About Regeneron Pharmaceuticals

Founded and led by physician-scientists, Regeneron (NASDAQ: REGN) is a prominent biotechnology company that focuses on inventing and developing medicines for serious diseases. The company's innovation enables it to create not only approved treatments but also several product candidates currently under development, many of which originate from its own laboratories. The therapeutic areas covered by Regeneron's medicines include eye diseases, allergic and inflammatory diseases, various cancers, cardiovascular and metabolic diseases, neurological conditions, hematologic disorders, infectious diseases, and rare diseases.

Regeneron is at the forefront of scientific discovery and expedites drug development through proprietary technologies such as VelociSuite^®, which generates optimized fully human antibodies along with new classes of bispecific antibodies. The company harnesses data-powered insights from the Regeneron Genetics Center^®, pioneering genetic medicine initiatives to identify innovative treatment targets and approaches.

For further details, interested parties can visit Regeneron or follow them on social media platforms like LinkedIn, Instagram, Facebook, or X.

Regeneron, Financials, Conference